Che Lin Kim

Che Lin Kim is a biotechnology specialist with extensive experience in upstream biopharmaceutical manufacturing. Currently serving as a Specialist at Lundbeck since June 2024, Che Lin Kim previously held the position of Senior Scientist at LEO Pharma, leading early- and late-stage monoclonal antibody (mAb) programs, and developing biopharmaceutical processes. Che Lin Kim's experience encompasses work at various esteemed organizations, including scientific advisory roles, postdoctoral research focused on genetic improvements for enzyme production, and advanced research in therapeutic protein production. Holding a PhD in Biotechnology from the Korea Advanced Institute of Science and Technology, Che Lin Kim has contributed significantly to the fields of genome engineering and cultivation process optimization.